###### Strengths and limitations of this study

This is a novel presurgical weight-loss trial for women with stage 0--II breast cancer that will explore the effect of an acute period of negative energy balance on tumour biology on a molecular level as well as circulating biomarkers within the host environment.This study is aimed at feasibility and therefore may lack the power to determine the impact of negative energy balance on tumour biology and relevant circulating biomarkers.

Introduction {#s1}
============

Breast cancer is the second most common cancer among women in the USA after skin cancer. In 2016, an estimated 61 000 new cases of ductal carcinoma in situ (DCIS) and 246 660 new cases of invasive breast cancer will be diagnosed, with 40 450 individuals dying of this disease.[@R1] [@R2] Many studies have shown that overweight and obesity are associated with an increased risk of postmenopausal breast cancer; most recently comprehensive meta-analysis has reported that the relative risk of postmenopausal breast cancer was 1.05 (95% CI 1.03 to 1.07) per 2 kg/m^2^ increase in body mass index (BMI).[@R3] Moreover, obesity is linked to poorer prognosis, that is, increased disease-specific and overall mortality, among premenopausal and postmenopausal women.[@R4] Currently, the exact mechanisms that link obesity to cancer progression are unknown, though it is surmised that complex interactions among multiple factors are involved.[@R5] In breast cancer, various growth factors, inflammatory markers, adipokines and hormones, such as oestradiol and insulin, are likely to play roles and are influenced by weight status.[@R8] It is speculated that the microbiome also may play a role in breast cancer related to systemic oestrogen levels and obesity.[@R11] [@R12] Similarly, there are numerous observational studies linking insulin to breast cancer. Several weight loss intervention trials have shown that negative energy balance via caloric restriction and/or increased physical activity results in lower insulin levels.[@R5] [@R13] It has been proposed that weight loss has potential as a therapeutic strategy to slow disease progression, not only for women with DCIS, but also for those who have invasive disease.[@R14] We aim to explore the feasibility of weight loss in this patient population, and describe the potential impact that weight loss invokes on tumour biology and the host environment, assessing effects on biomarkers and gene expression in the tumour and circulation using serum and peripheral blood mononuclear cells (PBMCs).

This research builds on our similarly designed phase II randomised controlled trial (RCT) in prostate cancer, in which we also use a presurgical model to explore whether we are able to affect tumour biology with brief exposure to a modified diet.[@R17] While analyses of those results are currently underway, we observed significantly reduced tumour proliferation rates (Ki-67) in men with prostate cancer who received 30 g of ground flaxseed daily in another presurgical trial which also employed a 3-week intervention period.[@R18] Secondary analysis showed that tumour levels of cytokines and angiogenic factors associated with the convergence of hormones, inflammation and energy-related factors (CHIEF) pathway, for example, vascular endothelial growth factor (VEGF), were also responsive to the brief period of dietary manipulation, as well as to weight status.[@R8] [@R18] We postulate similar effects in early-stage breast cancer through biological and biobehavioural pathways in which weight loss may affect cancer progression.

Methods and analysis {#s2}
====================

Study design {#s2a}
------------

Initially, the study was designed as a two-arm presurgical RCT among 40 overweight or obese postmenopausal women with DCIS (stage 0 breast cancer) in which overweight and obesity are hypothesised as key in the aetiology and progression of disease. However, due to slow accrual and because obesity is related to mortality regardless of stage and age, we expanded our eligibility criteria to include premenopausal and peri-menopausal women, as well as those with stage I and II breast cancer.[@R4] Consenting patients are randomised to one of the two study arms after completion of their baseline assessment. Attention control and experimental arms receive diet counselling during the study period to correct nutritional deficiencies with food sources, as well as instruction on progressive resistance training (PRT) of the upper body using Therabands (Hygenic Corporation, Akron, Ohio, USA). The experimental arm receives PRT plus mentored aerobic exercise and diet counselling for caloric restriction to promote a weight loss of up to 0.91 kg/week ([figure 1](#BMJOPEN2016012320F1){ref-type="fig"}). Participants in each of the study arms are contacted at least twice weekly by study staff. All participants undergo follow-up assessment immediately prior to surgery.

![Study schema. BMI, body mass index; PRT, progressive resistance training.](bmjopen2016012320f01){#BMJOPEN2016012320F1}

Outcomes {#s2b}
--------

While the primary outcomes relate to feasibility, that is, whether the study is able to accrue and retain at least 80% of the sample and result in no serious adverse events attributable to the intervention, a key biological outcome of interest is tumour proliferation rates (Ki-67) in breast tumours and tissue between the experimental and attention control arms. Based on the results of our prior diet and exercise trials, we speculate that in comparison to the attention control arm with stable weight, the experimental arm will lose weight and exhibit decreases in Ki-67, though we acknowledge that such analyses are exploratory and may be insufficiently powered. While our accrual has been slower than anticipated, thus far and with more than half of our sample enrolled, we have observed excellent rates of retention and no serious adverse events.

Secondary outcomes are to explore improvements in other biomarkers. These changes are studied in relation to the following end points: (1) adiposity measures, that is, body weight, waist circumference (WC) and per cent body fat from dual-energy X-ray absorptiometry (DXA); (2) energy intake and nutrient density of the diet; (3) time, frequency, and intensity of physical activity via self-report and accelerometry; (4) cardiorespiratory fitness; (5) tumour markers and phosphoro-proteins on the CHIEF pathway in tumour; (6) gene expression profiles in tumour and PBMCs; (7) serum levels of insulin, leptin, estradiol, VEGF, tumour necrosis factor α (TNFα), and sex hormone-binding globulin (SHBG); (8) changes in the salivary and faecal microbiome; and (9) quality of life (QoL).

Recruitment/consent {#s2c}
-------------------

Cases are recruited from the University of Alabama at Birmingham (UAB) Kirklin Interdisciplinary Breast Health Clinic (Birmingham, Alabama, USA)*.* A thorough explanation of the study and printed materials are provided to all patients who meet general screening criteria, that is, overweight or obese (BMI of 25--60 kg/m^2^) with histopathologically confirmed stage 0--II breast cancer who will receive surgical treatment. Data on age, race, BMI and mileage from residence to UAB are collected on all patients approached; these data are de-identified and stored with the stated reason for refusal or reasons for ineligibility. At trial completion, we will analyse data to discern if refusers and ineligibles differ from enrolees on demographic factors since such data are vital to assess generalisability of findings.

Eligibility and exclusion {#s2d}
-------------------------

This study accrues overweight or obese women with stage 0--II breast cancer who: (1) elect surgery with more than 3 weeks lag-time between the start of the intervention and their scheduled surgery; (2) have no pre-existing medical conditions that preclude adherence to unsupervised exercise---we screen potential participants with the Physical Activity Readiness Questionnaire (PAR-Q),[@R19] and obtain physician clearance for any conditions affirmed by patients, including resting blood pressures \>99 diastolic or \>159 systolic or cardiac abnormality; (3) have no current medical condition that affects weight status, such as Cushing\'s syndrome or untreated hypothyroidism; (4) have no additional active malignancy; (5) are English speaking/reading since all survey instruments are not validated in other languages; (6) are not currently enrolled in a weight loss programme; and (7) are willing to be assigned to either study arm and adhere to the protocol. Written informed consent is obtained from all interested and eligible women.

Baseline assessment {#s2e}
-------------------

Study measures are outlined in [table 1](#BMJOPEN2016012320TB1){ref-type="table"}. Data regarding scheduled surgery, demographics, medical history, medication-use and comorbidities (Older American Resources and Services (OARS) comorbidity scale) are collected and logged.[@R20] QoL is measured, given the potential of weight loss to improve emotional well-being and overall health. Of the many instruments to measure QoL, the Functional Assessment of Cancer Therapy for Breast Cancer (FACT-B) was selected as it assesses weight concerns and has been validated in newly diagnosed patients with breast cancer.[@R23] Self-reported physical activity is collected using the Godin Leisure Time Physical Activity Questionnaire.[@R24] A programmed accelerometer (wGT3X: Actigraph, LLC, Pensacola, Florida, USA), worn at the hip during waking hours (∼06:00 to 22:00), is used to capture objective activity data. While a 7-day collection period is ideal for accelerometry, the brevity of the presurgical period constrained our collection to 3 days.[@R25] Epoch length during initialisation of the accelerometer is set to 60 s, non-wear time is defined as 60 min of no activity and a valid day is defined as at least 10 hours of valid wear time. Moderate physical activity is defined as 1952--5724 counts/min, vigorous physical activity as 5725--9498 counts/min and very vigorous as \>9498 counts/min.[@R26] Two dietary recalls (1 weekday and 1 weekend day) are taken at each time point using a multiple-pass method and the Nutrition Data System for Research (NDSR 2014, Minneapolis, Minnesota, USA) for dietary analysis.

###### 

Schedule for measurement, testing and assessment at baseline and follow-up visits

  Measures                                                                                          Baseline   Follow-up
  ------------------------------------------------------------------------------------------------- ---------- -----------
  Anthropometric measures                                                                                      
   Weight                                                                                           X          X
   Height                                                                                           X          
   BMI (kg/m^2^)                                                                                    X          X
   Waist circumference                                                                              X          X
   Body composition (DXA)                                                                           X          X
  Components of energy balance (antecedents to change in BMI)                                                  
   Dietary intake (1-weekday and 1-weekend day) by a registered dietitian                           X          X
   Godin leisure time physical activity questionnaire                                               X          X
   Physical activity data captured via accelerometry (3-day period)                                 X          X
   Cardiorespiratory fitness (VO~2~ submax)                                                         X          X
  Tumour markers                                                                                               
   Ki-67, I-R, VEGF, TNFα, NFκB, 4E-BP1, activated caspase-3 and p16 in paraffin-embedded tumours   X          X
   *p-Akt, p-GSK-3β, p-p70S6K, p-S6RP* for fresh-frozen tumour                                      X\*        X
  Gene expression using multi array                                                                            
   Insulin (I-R), leptin (LEPR), VEGF (VEGFR) and TNF (FAS) in tumours                              X          X
   Insulin (I-R), leptin (LEPR), VEGF (VEGFR), TNF (FAS) and apoptosis regulator (Bcl-2) in PBMCs   X          X
  Serum biomarkers                                                                                             
   Insulin, leptin, estradiol, VEGF, TNFα, SHBG                                                     X          X
  Microbiome profiles                                                                                          
   Saliva                                                                                           X          X
   Faeces                                                                                           X          X
  Quality of life                                                                                              
   FACT-B (questionnaire)                                                                           X          X
  Demographics/comorbidities                                                                                   
   Demographics---race, age, educational level                                                      X          
   Medical history and medications                                                                  X          X
   OARS comorbidity scale                                                                           X          X

\*Diagnostic specimens are optionally obtained after study enrolment.

BMI, body mass index; DXA, dual-energy X-ray absorptiometry; FACT-B, Functional Assessment of Cancer Therapy Questionnaire for Breast Cancer; I-R, insulin receptor; LEPR, leptin receptor; NFκB, nuclear factor κ-light-chain-enhancer of activated B cells; OARS, Older American Resources and Services; PBMCs, peripheral blood mononuclear cells; SHBG, sex hormone-binding globulin; TNFα, tumour necrosis factor α; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.

VO~2~ SubMax testing (Trackmaster Treadmills Model TMX425CP, Full Vision., Newton, Kansas, USA) is performed per the guidelines of the American College of Sports Medicine (ACSM) and using the Naughton protocol. Fitness is determined by estimating the oxygen cost of walking at the treadmill incline and speed achieved at 85% of predicted maximal heart rate (MHR) using published regression equations and expressed in mL/kg/min.[@R27] [@R28]

Anthropometric measures of weight, height and WC are performed using protocols defined by the Anthropometric Standardisation Manual, with measures taken to the nearest tenth of a kilogram or centimetre.[@R29] BMI is calculated using the Quetelet equation of kg/m^2^. Body composition is assessed using DXA (Lunar iDXA, GE Healthcare, Waukeha, Wisconsin, USA) on a densitometer which is calibrated at least daily using an anthropomorphic phantom.

Fasting blood (20 mL) is collected and configured into sera, plasma and buffy coat. Half of the buffy coat is stored in RNAlater (Thermo Fisher Scientific, Grand Island, New York, USA) and the remaining buffy coat is stored as is. To assess any changes in the microbiome, 3 mL of saliva is collected in a test tube and faecal samples are collected using a sterile wipe. Recent antibiotic intake is self-reported on sample collection. All samples are stored at −80°C until batch analysis.

If women consent to an additional biopsy, biopsies are performed with a 14 G needle under ultrasound guidance and tissue is fresh frozen. The optional collection of fresh tissue at baseline is later compared with postintervention samples obtained at the time of surgery. All pathology reports of biopsies are reviewed for breast cancer subtype, and biopsy tissues are accessed for gene expression and immunohistochemistry. Paraffin-embedded tissues are available at baseline for all participants. Given the brevity of the presurgical period, these assessments are scheduled within 1-week of diagnosis.

Randomisation {#s2f}
-------------

Given that this was a feasibility trial with power calculated to detect differences in weight change between study arms, we stratified on the primary factor that would differentiate future weight loss, that is, current BMI status.[@R17] BMI groups of 25.5--29.9 and 30.0--60.0, and with block sizes of 4, is used for this trial. At the initiation of the trial, randomisation sequences were generated by the study statistician (RAO) and assignments were placed in sealed envelopes. As participants complete their baseline assessments, their envelope is opened in the order it was generated and their assignment is recorded. Assignments are re-verified with the statistician to assure fidelity with the randomisation process.

Attention control intervention {#s2g}
------------------------------

An attention control arm is implemented to enhance interest in the trial and improve study accrual and retention. Given concern regarding lymphoedema, we provide PRT as a means of 'pre-habilitation' and strengthening the arm prior to surgery.[@R30] [@R31] An ACSM-certified Cancer Exercise Trainer (CET) provides guidance on three resistance band exercises that target the triceps, biceps and deltoids.[@R32] In addition, participants receive dietary counselling by a registered dietitian (RD) to correct nutrient deficiencies (with food sources rather than supplements) that are detected by the NDSR analysis of their 2-day dietary recalls conducted at baseline.[@R33]

Experimental intervention {#s2h}
-------------------------

The same PRT protocol and dietary guidance described above are offered as part of the experimental intervention. Experimental arm participants also receive additional intensive counselling to achieve a weight loss of 0.68--0.919 kg/week. We estimate energy needs using the Mifflin-St. Jeor equation and a multiplier which assumes sedentary behaviour, that is, 1.2 (10×(body weight in kg)+6.25 (height in cm)---5(age)) and then subtract 750--1000 kcal/day.[@R34] Participants are trained on how to achieve this caloric deficit through dietary caloric restriction and increased physical activity. Participants are provided a choice of either counting their calories, following a prescribed meal plan or using a 'Choose Your Foods' exchange list system endorsed by the American Diabetes Association and the Academy of Nutrition and Dietetics.[@R35] [@R36] A healthy, nutritionally adequate diet that meets the Dietary Reference Intakes, with food choice patterns consistent with American Cancer Society and World Cancer Research Fund/American Institute of Cancer Research guidelines is recommended.[@R37] Guidance is provided regarding portion control, dietary restraint and replacing nutrient poor and high energy foods with nutrient rich and low energy foods.

An exercise programme is tailored taking into account energy expenditure for various activities; physical activity-associated expenditures of 200--400 kcal/day serves as a goal. Aerobic training of large leg muscles is emphasised to achieve a greater energy deficit, and ramping of intensity and volume over time is pursued per ACSM guidelines.[@R41] Participants train once to twice weekly under the supervision of the CET, and are encouraged to exercise at home using a heart rate monitor to assure fidelity to the training programme. Onsite weighing occurs at the beginning of each supervised training session.

Social cognitive theory (SCT) is used as the behavioural framework to guide the intervention.[@R42] Self-monitoring is a key concept of SCT, and participants are provided with a scale, pedometers or Fitbits, and asked to log their body weight, foods eaten along with accompanying calorie or exchange list values and physical activity behaviours daily. The CET and RD interact with patients at least twice weekly and begin by reviewing current intake and activity levels, adjusting intake, fielding questions, providing support and problem-solving to overcome barriers, and setting goals for the upcoming week.

Follow-up assessment {#s2i}
--------------------

On the day of or the day prior to surgery, a follow-up appointment is scheduled. At this time, measures taken at the baseline assessment are repeated, except for height and the demographic survey. At surgery, fresh-frozen tumour tissue and adjacent adipose tissue is obtained. Later, paraffin-embedded tissue is collected from the Department of Pathology at UAB.

Tissue processing {#s2j}
-----------------

All tumour blocks are reviewed by a pathologist at the Tissue Collection and Banking Facility at UAB to confirm atypical lesions. Immunostaining for Ki-67, insulin receptor (I-R), VEGF, TNFα, nuclear factor κ-light-chain-enhancer of activated B cells (NFκB), 4E-BP1, activated caspase-3, and p16 is then performed. Whole tissue lysates are extracted from fresh-frozen tumour to determine levels of phosphorylated Akt, GSK-3β, p70S6K and S6RP (phosphoproteins on the CHIEF pathway) in the Physiology and Metabolism core at UAB.

Serum processing {#s2k}
----------------

Serum assays for insulin, leptin, VEGF, TNFα and SHBG are performed in the Physiology and Metabolism core at UAB. Insulin and SHBG are assayed by immunofluorescence on a TOSOH AIA-600 II Automated Immunoassay Analyzer (TOSOH Bioscience, South San Francisco, California, USA); minimum sensitivity of 0.5 µU/mL for insulin and 0.104 nmol/L for SHBG, intra-assay coefficients of variance (CV) of 1.49% for insulin and 1.61% for SHBG, and interassay CV of 4.42% for insulin and 5.60% for SHBG. Leptin is measured using a Human Leptin RIA kit (EMD Millipore, Billerica, Massachusetts, USA); minimum sensitivity of 0.92 ng/mL, intra-assay CV of 6.61% and interassay CV of 7.13%. VEGF and TNFα are measured using a multiplex proinflammatory assay on the SECTOR imager 2400 (Meso Scale Diagnostics, Rockville, Maryland, USA); minimum sensitivity of 0.92 pg/mL for VEGF and 0.11 pg/mL for TNFα, intra-assay CV of 8.63% for VEGF and 4.57% for TNFα, and interassay CV of 14.20% for VEGF and 10.90% for TNFα.

Serum assays for estradiol are performed at the Quest Diagnostics Nichols Institute (San Juan Capistrano, California, USA). The Quest Diagnostics Nichols Institute performs oestrogen extraction and analysis using mass spectrometry which is important in postmenopausal women who often have minimal levels of oestrogen.

Gene expression {#s2l}
---------------

Gene expression analyses are performed on RNA from microdissected tumour specimens and PBMCs that are isolated from the buffy coat stored in RNAlater. Total RNA is extracted from the samples using a Trizol reagent (Invitrogen, Carlsbad, California, USA) and RNeasy Mini Kit (QIAGEN, Valencia, California, USA) according to the manufacturer\'s instructions. The concentration and purity of total RNA is determined using a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, California, USA). At the UAB Comprehensive Cancer Center Shared Genomics Resource, samples are purified to cDNA. After conversion to biotin-labelled cRNA, they are hybridised to a HumanHT-12 v4 Expression BeadChip (Illumina, San Diego, California, USA) and stained with strepavidin-Cy3 for visualisation. Though select genes have been identified specifically on the CHIEF pathway, the HumanHT-12 v4 Expression BeadChip contains sequences representing ∼47 231 curated and putative genes and expressed sequence tags. Quality standards for hybridisation, labelling, staining, background signal and basal level of housekeeping gene expression for each chip is verified on all assays. After scanning the probe array, the resulting image is analysed using GenomeStudio software (Illumina). Gene lists are created by exporting the data from GenomeStudio into GeneSpring (V.11.5.1, Agilent Technologies). The data inside GeneSpring are first normalised using the Robust Multiarray (RMA) method and background is subtracted from the median of all samples. Samples are then filtered based on the flags present and marginal, thereby removing absent flags.

Gut microbiome {#s2m}
--------------

At each time point, participants collect faecal and saliva samples in order to explore if changes in physical activity and dietary intake affect the microbiome. Faecal samples are collected after a bowel movement using a sterile wipe which is then placed in a plastic bag and immediately frozen. Saliva samples are collected in a 50 mL Falcon tube prior to brushing teeth on the assessment day. Both sets of specimens are stored at −80°C and delivered to the Microbiome/Bioinformatic/Gnotobiotic Animal Core at UAB where microbiome analysis is conducted.

Microbiome analysis targeting the V4 region of the 16S rRNA gene is performed using an Illumina MiSeq and employing similar quality assurance methods as described previously.[@R7] [@R13] [@R17] Analyses of the microbiome samples are performed using the Quantitative Insight into Microbial Ecology (QIIME) suite, V.1.7 and a QIIME wrapper (QWRAP) as described previously.[@R43]

Power and sample size calculations {#s2n}
----------------------------------

Data from our previous UAB weight loss programmes indicate a mean weight loss over 3--4 weeks of 2.82±1.57 kg, which was used to estimate power. Initially, 40 participants with 20 per arm were planned, and a drop-out rate of 20% was assumed, that is, 16 per arm. Sample sizes of 14--16 per arm yield \>90% power to detect a difference in the means of 2.82 kg, assuming a two-group, two-sided t-test and a significance level of 5%.

Statistical analysis {#s2o}
--------------------

Given the exploratory nature of this work, our analysis will rely heavily on descriptive statistics, such as means, SDs, frequencies and proportions, which will be calculated for each study arm, and explored within subgroups of interest, that is, patients of differing cancer stage, and of premenopausal and postmenopausal status. Comparisons of baseline characteristics between enrolled participants and potential participants who refused to participate, as well as between participants who completed the study and those dropped out, are compared using the two-group t-test for continuous variables and the Pearson χ^2^ test for categorical variables. Biomarkers and anthropometric change scores are also compared between the groups using the two-group t-test. Overall changes in measures from baseline to postintervention may be examined using the paired t-test. Adverse events are summed as frequencies and are compared between the two groups using the Pearson χ^2^ test. The primary method of analysis will be mixed models repeated-measures analyses, such as repeated-measures analysis of covariance. When a model term is statistically significant, the Tukey-Kramer multiple comparisons test will be used to determine which specific pairs of means are significantly different. This method allows us to compare changes over time (within-group changes) and differences between groups simultaneously. These models include terms for group (study arm), time (baseline, follow-up) and group×time, as well as terms for interactions that are of scientific interest. Variables such as select demographic (eg, race and menopausal status) and tumour factors (eg, cancer stage) are accounted for in these analyses.

Relationships between serum and tissue markers and adiposity are examined using the Pearson correlation analysis. Distributions of continuous variables are examined using stem-and-leaf plots, normal probability plots and the Kolmogorov-Smirnov test. Variables that are determined to deviate greatly from a normal distribution are transformed prior to analysis or are analysed using non-parametric tests such as the Wilcoxon rank-sum and signed-rank tests. Statistical tests are two-sided and are performed using a 5% significance level. SAS software (V.9.4; Cary, North Carolina, USA) is used to conduct the statistical analyses.

Trial status {#s2p}
------------

This trial opened for recruitment 21 August 2014, with recruitment expected to be completed by August 2016. At the time of submission of this study protocol, 85 potentially eligible patients have been approached, 57 were found to be ineligible, 28 patients were enrolled and 26 patients have completed the study. One patient was excluded before the follow-up assessment due to findings of advanced cancer after the baseline assessment. Currently, our rate of drop-out is 3.5% (far lower than the 20% forecasted). One of the greatest barriers to recruitment has been the required 3 week lagtime between baseline assessment and surgery, as many prospective participants elect to have surgery as soon as possible. Other reasons for ineligibility are patient\'s overwhelming distress resulting from their cancer diagnosis and expressed concern that they 'just can\'t take on anything else', job/time conflicts and other responsibilities such as a caregiver role for family members. Currently, none of the enrolled patients have volunteered for an additional biopsy at baseline assessment; while this will preclude our ability to compare biomarkers in fresh-frozen tissue, we still will be able to conduct all assessments planned on paraffin-embedded samples.

Dissemination {#s3}
=============

As such, all adverse events are recorded and classified as either serious or non-serious. Serious adverse events include conditions that are fatal or life threatening, permanently disabling or which require prolonged hospitalisation. All other adverse events are considered non-serious. To date, no serious adverse events and non-serious events have occurred. The results of the study will be published in a peer-reviewed scientific journal after study completion.

Discussion {#s4}
==========

This is the first trial to track the effects of a presurgical weight loss intervention in women with early-stage breast cancer. Our study is unique because it uses a presurgical model which allows the opportunity to explore the impact of acute negative energy balance with weight loss directly on the tumour and at a molecular level, as well as systemically assessing select markers, gene expression, tumour proliferation and apoptosis, and QoL ([figure 2](#BMJOPEN2016012320F2){ref-type="fig"}).

![Logic model linking negative energy balance to increased tumour suppression. BMI, body mass index; I-R, insulin receptor; LEPR, leptin receptor; NFκB, nuclear factor κ-light-chain-enhancer of activated B cells; PBMCs, peripheral blood mononuclear cells; SHBG, sex hormone-binding globulin; TNFα, tumour necrosis factor α; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor; WC, waist circumference.](bmjopen2016012320f02){#BMJOPEN2016012320F2}

The CHIEF model proposed by Slattery and Fitzpatrick[@R8] provides a unifying framework that incorporates much of the energy, hormonal and inflammatory responses associated with energy balance. Our study will explore effects on metabolic markers within the CHIEF pathway as mediators by which negative energy balance affects tumour growth. Downstream of the CHIEF pathway are the PI3K and the mTOR signalling pathways which are currently being evaluated for drug development and are also affected by caloric restriction and increased physical activity.[@R46]

Our primary study limitations include a lack of statistical power to determine anything more than the feasibility of weight loss. Moreover, the sheer number of assessments in combination with a small sample size may increase the type 1 error, and result in inconclusive findings. However, it must be borne-in-mind that is a feasibility trial and one in which the exploration of other end points is strictly for the purposes of hypothesis generating (not testing). Another limitation is the substantial trade-offs inherent when a study is dependent on and integrated within a pre-surgical clinical care timeline. While it would be ideal to delay surgery more than a minimum of 3 weeks, in order to allow for longer accelerometry collection periods as well as longer intervention periods, further delay is seldom acceptable within the US healthcare system which schedules women for surgery on demand. Although the study period is brief, we will explore differences in tumour proliferation rates and cancer-related biomarkers within the span of 3 weeks as experienced in a similar study among patients with prostate cancer.[@R18]

In summary, this study builds on our prior work and extant clinical practice, utilises an appropriate and accessible patient population and is designed to gather data that will begin to improve our understanding of the effect of weight loss on breast cancer biology and related biomarkers and outcomes. Since weight loss is apt to be pursued as complementary care in the clinical setting, this study is further strengthened by its real-world approach. Indeed, we expect to uncover exciting findings that could ultimately influence the standard of care for treatment of early-stage breast cancer.
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